PIK3CA and AKT Gene Polymorphisms in Susceptibility to Osteosarcoma in a Chinese Population

  • He, Mao-Lin (Division of Spinal Surgery, The First Affiliated Hospital of Guangxi Medical University) ;
  • Wu, Yang (Division of Spinal Surgery, The First Affiliated Hospital of Guangxi Medical University) ;
  • Zhao, Jin-Min (Department of Orthopedic Trauma and Hand Surgery, The First Affiliated Hospital of Guangxi Medical University) ;
  • Wang, Zhe (Division of Spinal Surgery, The First Affiliated Hospital of Guangxi Medical University) ;
  • Chen, Ying-Bin (Division of Spinal Surgery, The First Affiliated Hospital of Guangxi Medical University)
  • Published : 2013.09.30


Purpose: To explore the association between PIK3CA and AKT single nucleotide polymorphisms(SNP) and osteosarcoma susceptibility. Methods: TaqMan polymerase chain reaction(PCR) was used to detect the genotypes of SNPs (rs7646409, rs6973569 and rs9866361) in peripheral blood samples from 59 patients with osteosarcoma and from 63 healthy controls. Unconditional logistic regression was used to analyze the correlation between SNPs and osteosarcoma risk. Results: No statistically significant difference was found between osteosarcoma patients and healthy controls in the genotype of AKT rs6973569 (P=0.7). However, after stratified analysis, the genotype AA of AKT rs6973569 carried a higher risk of osteosarcoma metastasis (OR:2.94, 95%CL:1.00-8.59); the difference of rs7646409 genotype distributions between the case and control groups was statistically significant (P=0.032). Taking genotype TT as a reference, the risk of osteosarcoma increased three fold in patients with genotype CC (OR:3.47, 95%CL:1.26-9.56). A statistically significant difference was found between the alleles C and T (P=0.005). Further analysis showed that the risk factor was more pronounced in male patients with Enneking's stage IIB and osteoblastic osteosarcoma. PIK3CA rs9866361 did not fit Hardy-Weinberg equilibrium (P<0.05). Conclusions: Genotype CC in locus PIK3CA rs7646409 may increase the risk of osteosarcoma in the Chinese population.


Osteosarcoma;single nucleotide polymorphisms;susceptibility;PIK3CA;AKT


  1. Chen J, Shao P, Cao Q, et al (2012). Genetic variations in a PTEN/AKT/mTOR axis and prostate cancer risk in a Chinese population. PLoS One, 7, e40817.
  2. Choy E, Hornicek F, MacConaill L, et al (2012). Highthroughput genotyping in osteosarcoma identifies multiple mutations in phosphoinositide-3-kinase and other oncogenes. Cancer, 118, 2905-14.
  3. Courtney KD, Corcoran RB, Engelman JA (2010). The PI3K pathway as drug target in human cancer. J Clin Oncol, 28, 1075-83.
  4. Gorlick R (2009). Current concepts on the molecular biology of osteosarcoma. Cancer Treat Res, 152, 467-78.
  5. Fendri A, Khabir A, Mnejja W, et al (2009). PIK3CA amplification is predictive of poor prognosis in Tunisian patients with nasopharyngeal carcinoma. Cancer Sci, 100, 2034-9.
  6. Foster L, Dall GF, Reid R, et al (2007). Twentieth-century survival from osteosarcoma in childhood. Trends from 1933 to 2004. J Bone Joint Surg Br, 89, 1234-8.
  7. Fresno Vara JA, Casado E, de Castro J, et al (2004). PI3K/ Akt signalling pathway and cancer. Cancer Treat Rev, 30, 193-204.
  8. Hameed M, Dorfman H (2011). Primary malignant bone tumors- -recent developments. Semin Diagn Pathol, 28, 86-101.
  9. Hildebrandt MA, Yang H, Hung MC, et al (2009). Genetic variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy. J Clin Oncol, 27, 857-71.
  10. Jiang BH, Liu LZ (2009). PI3K/PTEN signaling in angiogenesis and tumorigenesis. Adv Cancer Res, 102, 19-65.
  11. Linabery AM, Ross JA (2008). Trends in childhood cancer incidence in the U.S. (1992-2004). Cancer, 112, 416-32.
  12. Liu P, Cheng H, Roberts TM, et al (2009). Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov, 8, 627-44.
  13. Liu Y, Lv B, He Z, et al (2012). Lysyl oxidase polymorphisms and susceptibility to osteosarcoma. PLoS One, 7, e41610.
  14. Qian Y, Corum L, Meng Q, et al (2004). PI3K induced actin filament remodeling through Akt and p70S6K1: implication of essential role in cell migration. Am J Physiol Cell Physiol, 286, C153-63.
  15. Liu Z, Hou P, Ji M, et al (2008). Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. J Clin Endocrinol Metab, 93, 3106-16.
  16. Mure H, Matsuzaki K, Kitazato KT, et al (2010). Akt2 and Akt3 play a pivotal role in malignant gliomas. Neuro Oncol, 12, 221-32.
  17. Nakatani K, Thompson DA, Barthel A, et al (1999). Upregulation of Akt3 in estrogen receptor-deficient breast cancers and androgen-independent prostate cancer lines. J Biol Chem, 274, 21528-32.
  18. Rosty C, Young JP, Walsh MD, et al (2013). PIK3CA activating mutation in colorectal carcinoma: associations with molecular features and survival. PLoS One, 8, e65479.
  19. Samuels Y, Wang Z, Bardelli A, et al (2004). High frequency of mutations of the PIK3CA gene in human cancers. Science, 304, 554.
  20. Savage SA, Mirabello L, Wang Z, et al (2013). Genome-wide association study identifies two susceptibility loci for osteosarcoma. Nat Genet, 45, 799-803.
  21. Subbiah V, Kurzrock R (2011). Phase 1 clinical trials for sarcomas: the cutting edge. Curr Opin Oncol, 23, 352-60.
  22. Sung JS, Park KH, Kim ST, et al (2012). Discovery and evaluation of polymorphisms in the AKT2 and AKT3 promoter regions for risk of Korean lung cancer. Genomics Inform, 10, 167-74.
  23. Vivanco I, Sawyers CL (2002). The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer, 2, 489-501.
  24. Zhang L, Sun S, Zhou J, et al (2011). Knockdown of Akt1 promotes Akt2 upregulation and resistance to oxidativestress- induced apoptosis through control of multiple signaling pathways. Antioxid Redox Signal, 15, 1-17.
  25. Wang LE, Ma H, Hale KS, et al (2012). Roles of genetic variants in the PI3K and RAS/RAF pathways in susceptibility to endometrial cancer and clinical outcomes. J Cancer Res Clin Oncol, 138, 377-85.
  26. Xing JC, Tufano RP, Murugan AK, et al (2012). Single nucleotide polymorphism rs17849071 G/T in the PIK3CA gene is inversely associated with follicular thyroid cancer and PIK3CA amplification. PLoS One, 7, e49192.
  27. Xing M (2010). Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer. Thyroid, 20, 697-706.

Cited by

  1. Review of the Molecular Pathogenesis of Osteosarcoma vol.15, pp.15, 2014,
  2. Gemcitabine for the Treatment of Patients with Osteosarcoma vol.15, pp.17, 2014,
  3. Detection of PIK3CA Gene Mutations with HRM Analysis and Association with IGFBP-5 Expression Levels in Breast Cancer vol.15, pp.21, 2014,
  4. Clinicopathologic Features and Prognosis of Osteosarcoma in Turkish Adults vol.15, pp.8, 2014,
  5. GRM4 gene polymorphism is associated with susceptibility and prognosis of osteosarcoma in a Chinese Han population vol.31, pp.7, 2014,
  6. Polymorphisms in miRNA processing genes and their role in osteosarcoma risk vol.62, pp.5, 2015,
  7. Role of five small nucleotide polymorphisms in the VEGF gene on the susceptibility to osteosarcoma and overall survival of patients pp.1792-1082, 2015,
  8. RETRACTED ARTICLE: Common genetic variants in microRNA processing machinery genes are associated with risk and survival in patients with osteosarcoma vol.291, pp.1, 2016,
  9. MicroRNA-26a induces osteosarcoma cell growth and metastasis via the Wnt/β-catenin pathway vol.11, pp.2, 2015,